Hofseth Biocare ASA:
February 15, 2023 12:12 ET
|
Hofseth Biocare ASA
Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 ...
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
February 15, 2023 12:12 ET
|
Hofseth Biocare ASA
Hofseth International AS ("HI"), a close associate of Hofseth Biocare ASA's (the "Company") board member Roger Hofseth, has notified the Company that HI has made the following purchases of shares in...
Hofseth Biocare ASA: FOURTH QUARTER 2022 & FULL YEAR FINANCIAL REPORT
February 10, 2023 02:00 ET
|
Hofseth Biocare ASA
In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last year on an underlying basis, generating sales revenues of NOK 34m, compared to...
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
December 30, 2022 04:08 ET
|
Hofseth Biocare ASA
Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at an average price of NOK 2.91 per share. Jon Olav Ødegård is CEO and primary insider...
Hofseth Biocare ASA: THIRD QUARTER 2022 FINANCIAL REPORT
November 11, 2022 02:00 ET
|
Hofseth Biocare ASA
Highlights in the third quarter - HBC grew revenue by 105 % year-on-year shows strength of our business in uncertain times and during the third quarter, HBC signed contracts with new salmon...
Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT
October 17, 2022 03:24 ET
|
Hofseth Biocare ASA
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed...
Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
August 30, 2022 08:25 ET
|
Hofseth Biocare ASA
The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Tuesday 30 August 2022. All matters were approved according to the...
Hofseth Biocare ASA: HBC’S PROGO BIOACTIVE PEPTIDES NOW IS A “NEW DIETARY INGREDIENT” (NDI) FOR THE US FDA
August 29, 2022 02:44 ET
|
Hofseth Biocare ASA
Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo® Bioactive Peptides. Summary Highlights...
Hofseth Biocare ASA: SECOND QUARTER & H1 2022 FINANCIAL REPORT
August 26, 2022 02:00 ET
|
Hofseth Biocare ASA
HBC had gross operating revenues of NOK 25.8m (31.0m) in the second quarter. For the first half of 2022 HBC had revenues of NOK 56.6m (47.9m). Cost of sales (CoGS) amounted to NOK 17.7m (21.6m) in the...
Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
August 09, 2022 13:30 ET
|
Hofseth Biocare ASA
An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 30 August 2022 at 13:00 CET. Please find the notice to the General...